Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
SD, IL-13 Production Rate in IPF
The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT00532233
- Testing
- QAX576
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, double-blind, placebo-controlled safety and tolerability study of N-acetylcysteine or placebo in participants with mild to moderate idiopathic pulmonary fibrosis (IPF) receiving background…
- Trial name
- NCT02707640
- Testing
- N-acetylcysteine, Pirfenidone
- Where
- 69 sites in Austria, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Fibrosis, Pulmonary Hypertension
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's…
- Trial name
- NCT05356052
- Testing
- INOpulse
- Sponsor
- Bellerophon
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease
- Trial name
- NCT01203943
- Testing
- CC-930
- Where
- 22 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Celgene
Idiopathic Pulmonary Fibrosis
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT05389215
- Testing
- DWN12088
- Where
- 30 sites in United States, South Korea
- Volunteers
- 102 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis, Diarrhoea
A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib
This is an observational, non-interventional, and prospective post authorization safety study (PASS) that will describe the real-world proportion of patients that achieve nintedanib-associated diarrhoea control after 12 weeks of…
- Trial name
- NCT06200714
- Testing
- Nintedanib
- Where
- 8 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess…
- Trial name
- NCT06502379
- Testing
- AZD8965
- Where
- United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
- Trial name
- NCT06317285
- Testing
- GSK3915393
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550…
- Trial name
- NCT06241560
- Testing
- BI 1015550, Pirfenidone
- Where
- 3 sites in United States, Georgia
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon
Healthy Volunteers
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy female participants.
- Trial name
- NCT05985590
- Testing
- BMS-986278, Drospirenone/Ethinyl Estradiol
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared…
- Trial name
- CANAL (NCT04030026)
- Testing
- NAL ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Trevi Therapeutics
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Pulmonary Fibrosis, Tumor
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
This is a first-in-human, single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
- Trial name
- NCT05740475
- Testing
- 9MW3811 injection
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
A Trial of HRS-9813 in Healthy Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.
- Trial name
- NCT06821464
- Testing
- HRS-9813
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
- Conditions
- Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Trial name
- UPWARD (NCT07722507)
- Testing
- Antifibrotic therapy
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.
- Trial name
- NCT03538301
- Testing
- ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose)
- Where
- 33 sites in United States, Germany and 2 more
- Volunteers
- 123 people
- Sponsor
- Nitto Denko Corporation
Drug Interactions
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
- Trial name
- NCT06717100
- Testing
- Nintedanib 150 MG [Ofev]
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PureTech
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor…
- Trial name
- NCT00074698
- Testing
- FG-3019
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio